Nautilus Biotechnology to Announce Third Quarter of Fiscal Year 2021 Financial Results on November 2, 2021
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report its financial results for Q3 2021 on November 2, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) will report its financial results for Q3 2021 on November 2, 2021. Prior to the market open, the company will hold a webcast at 5:30 a.m. PT / 8:30 a.m. ET to discuss its results and business developments. Nautilus is focused on a single-molecule protein analysis platform aimed at revolutionizing proteomics and enhancing human health and medicine.
Positive
- Scheduled Q3 2021 financial results announcement on November 2, 2021.
- Webcast planned to discuss business developments and financial results.
Negative
- None.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was -3.72%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal year 2021 before market open on Tuesday, November 2nd, 2021.
The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Contacts
Investors:
InvestorRelations@nautilus.bio
Media:
Thermal for Nautilus Biotechnology
Kaustuva Das
Press@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.